Terms: = Breast cancer AND PTPRC, LCA, 5788, ENSG00000081237, T200, GP180, B220, LY5, CD45 AND Treatment
99 results:
1. Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing.
Demeule M; Currie JC; Charfi C; Zgheib A; Cousineau I; Lullier V; Béliveau R; Marsolais C; Annabi B
Front Immunol; 2024; 15():1355945. PubMed ID: 38482021
[TBL] [Abstract] [Full Text] [Related]
2. Relationship between immune checkpoint proteins and neoadjuvant chemotherapy response in breast cancer.
Kina Kilicaslan U; Aru B; Aydin Aksu S; Vardar Aker F; Yanikkaya Demirel G; Gurleyik MG
Surg Oncol; 2024 Feb; 52():102037. PubMed ID: 38290327
[TBL] [Abstract] [Full Text] [Related]
3. Isolation of Viable Epithelial and Mesenchymal Circulating Tumor Cells from breast cancer Patients.
Topa J; Żaczek AJ; Markiewicz A
Methods Mol Biol; 2024; 2752():43-52. PubMed ID: 38194026
[TBL] [Abstract] [Full Text] [Related]
4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
5. [treatment of paclitaxel and doxorubicin changes the immune microenvironment of breast cancer and inhibits the growth of tumor cells in mice].
Wang R; Lang L; Chen S; Wan X; Hou Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Oct; 39(10):891-897. PubMed ID: 37882712
[TBL] [Abstract] [Full Text] [Related]
6. NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells.
Campos-Mora M; Jacot W; Garcin G; Depondt ML; Constantinides M; Alexia C; Villalba M
Front Immunol; 2023; 14():1199594. PubMed ID: 37593736
[TBL] [Abstract] [Full Text] [Related]
7. A PDA-Functionalized 3D Lung Scaffold Bioplatform to Construct Complicated breast Tumor Microenvironment for Anticancer Drug Screening and Immunotherapy.
Zhang W; Chen Y; Li M; Cao S; Wang N; Zhang Y; Wang Y
Adv Sci (Weinh); 2023 Sep; 10(26):e2302855. PubMed ID: 37424037
[TBL] [Abstract] [Full Text] [Related]
8. Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer.
Carter JM; Chumsri S; Hinerfeld DA; Ma Y; Wang X; Zahrieh D; Hillman DW; Tenner KS; Kachergus JM; Brauer HA; Warren SE; Henderson D; Shi J; Liu Y; Joensuu H; Lindman H; Leon-Ferre RA; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Knutson KL; Goetz MP; Perez EA; Thompson EA
Nat Commun; 2023 Apr; 14(1):2215. PubMed ID: 37072398
[TBL] [Abstract] [Full Text] [Related]
9. A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells.
Donnenberg VS; Luketich JD; Sultan I; Lister J; Bartlett DL; Ghosh S; Donnenberg AD
Front Immunol; 2023; 14():1157697. PubMed ID: 37063842
[TBL] [Abstract] [Full Text] [Related]
10. High-purity isolation platelets by gradient centrifugation plus filtration.
Jin J; Shao Y; Zhang J; Cao J; Tao Z; Hu X
Int J Lab Hematol; 2023 Apr; 45(2):187-194. PubMed ID: 36470678
[TBL] [Abstract] [Full Text] [Related]
11. Quantitative multiplexed analysis of MMP-11 and cd45 in metastatic breast cancer tissues by immunohistochemistry-assisted LA-ICP-MS.
Johnson D; Clases D; Fernández-Sánchez ML; Eiro N; González LO; Vizoso FJ; Doble PA; Gonzalez de Vega R
Metallomics; 2022 Aug; 14(8):. PubMed ID: 35867868
[TBL] [Abstract] [Full Text] [Related]
12. Varying severities of symptoms underline the relevance of personalized follow-up care in breast cancer survivors: latent class cluster analyses in a cross-sectional cohort.
de Ligt KM; de Rooij BH; Walraven I; Heins MJ; Verloop J; Siesling S; Korevaar JC; van de Poll-Franse LV
Support Care Cancer; 2022 Oct; 30(10):7873-7883. PubMed ID: 35727375
[TBL] [Abstract] [Full Text] [Related]
13. Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic breast cancer.
Cardinali B; De Luca G; Tasso R; Coco S; Garuti A; Buzzatti G; Sciutto A; Arecco L; Villa F; Carli F; Reverberi D; Quarto R; Dono M; Del Mastro L
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682999
[TBL] [Abstract] [Full Text] [Related]
14. Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer.
Yellapu NK; Ly T; Sardiu ME; Pei D; Welch DR; Thompson JA; Koestler DC
BMC Cancer; 2022 Jun; 22(1):627. PubMed ID: 35672711
[TBL] [Abstract] [Full Text] [Related]
15. Early Diagnostic Markers and Therapeutic Targets for Experimental breast cancer.
Ermakova NN; Pershina OV; Zhukova MA; Pakhomova AV; Pan ES; Sandrikina LA; Krupin VA; Rybalkina OY; Dygai AM; Skurikhin EG
Bull Exp Biol Med; 2022 Apr; 172(6):747-751. PubMed ID: 35501655
[TBL] [Abstract] [Full Text] [Related]
16. Lithocholic acid conjugated mPEG-b-PCL micelles for pH responsive delivery to breast cancer cells.
Isik G; Kiziltay A; Hasirci N; Tezcaner A
Int J Pharm; 2022 Jun; 621():121779. PubMed ID: 35500691
[TBL] [Abstract] [Full Text] [Related]
17. Evaluation of the Effects of Anti-PD-1 Therapy on Triple-Negative breast cancer in Mice by Diffusion Kurtosis Imaging and Dynamic Contrast-Enhanced Imaging.
Tang WJ; Yao W; Jin Z; Kong QC; Hu WK; Liang YS; Chen LX; Chen SY; Zhang QQ; Wei XH; Xu XD; Guo Y; Jiang XQ
J Magn Reson Imaging; 2022 Dec; 56(6):1912-1923. PubMed ID: 35499275
[TBL] [Abstract] [Full Text] [Related]
18. Immune effects of CDK4/6 inhibitors in patients with HR
Scirocchi F; Scagnoli S; Botticelli A; Di Filippo A; Napoletano C; Zizzari IG; Strigari L; Tomao S; Cortesi E; Rughetti A; Marchetti P; Nuti M
EBioMedicine; 2022 May; 79():104010. PubMed ID: 35477069
[TBL] [Abstract] [Full Text] [Related]
19. Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative breast cancer.
Singh S; Lee N; Pedroza DA; Bado IL; Hamor C; Zhang L; Aguirre S; Hu J; Shen Y; Xu Y; Gao Y; Zhao N; Chen SH; Wan YW; Liu Z; Chang JT; Hollern D; Perou CM; Zhang XHF; Rosen JM
Cancer Res; 2022 Jun; 82(12):2281-2297. PubMed ID: 35442423
[TBL] [Abstract] [Full Text] [Related]
20. Heterogeneity of posttraumatic stress, depression, and fear of cancer recurrence in breast cancer survivors: a latent class analysis.
Malgaroli M; Szuhany KL; Riley G; Miron CD; Park JH; Rosenthal J; Chachoua A; Meyers M; Simon NM
J Cancer Surviv; 2023 Oct; 17(5):1510-1521. PubMed ID: 35224684
[TBL] [Abstract] [Full Text] [Related]
[Next]
